Your browser is no longer supported. Please, upgrade your browser.
Ensysce Biosciences, Inc.
Index- P/E12.58 EPS (ttm)0.45 Insider Own33.90% Shs Outstand6.22M Perf Week-19.28%
Market Cap138.88M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month-61.01%
Income2.90M PEG- EPS next Q- Inst Own14.50% Short Float- Perf Quarter-55.55%
Sales- P/S- EPS this Y978.50% Inst Trans- Short Ratio0.04 Perf Half Y-51.75%
Book/sh0.30 P/B18.83 EPS next Y- ROA22.50% Target Price- Perf Year-47.34%
Cash/sh0.00 P/C- EPS next 5Y- ROE107.10% 52W Range5.55 - 23.99 Perf YTD-54.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.45% Beta-0.11
Dividend %- Quick Ratio0.70 Sales past 5Y- Gross Margin- 52W Low1.80% ATR1.25
Employees- Current Ratio0.70 Sales Q/Q-70.90% Oper. Margin- RSI (14)15.89 Volatility16.28% 13.82%
OptionableNo Debt/Eq0.26 EPS Q/Q-197.80% Profit Margin- Rel Volume767.45 Prev Close5.56
ShortableYes LT Debt/Eq0.26 Earnings- Payout0.00% Avg Volume124.80K Price5.65
Recom- SMA20-42.49% SMA50-53.87% SMA200-54.34% Volume6,733,371 Change1.62%
Jul-26-21 08:00AM  
Jul-21-21 08:00AM  
Jul-08-21 08:00AM  
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.